POINT Biopharma Global PNT Stock
POINT Biopharma Global Price Chart
POINT Biopharma Global PNT Financial and Trading Overview
| POINT Biopharma Global stock price | 12.5 USD |
| Previous Close | 9.94 USD |
| Open | 9.91 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 800 |
| Day's Range | 9.75 - 10.02 USD |
| 52 Week Range | 5.59 - 11.13 USD |
| Volume | 341.47K USD |
| Avg. Volume | 683.76K USD |
| Market Cap | 1.04B USD |
| Beta (5Y Monthly) | 0.124533 |
| PE Ratio (TTM) | 9.617648 |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.6 USD |
PNT Valuation Measures
| Enterprise Value | 620.56M USD |
| Trailing P/E | 9.617648 |
| Forward P/E | -12.111112 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.39274 |
| Price/Book (mrq) | 2.1975806 |
| Enterprise Value/Revenue | 2.629 |
| Enterprise Value/EBITDA | 5.125 |
Trading Information
POINT Biopharma Global Stock Price History
| Beta (5Y Monthly) | 0.124533 |
| 52-Week Change | 24.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.13 USD |
| 52 Week Low | 5.59 USD |
| 50-Day Moving Average | 8.77 USD |
| 200-Day Moving Average | 7.92 USD |
PNT Share Statistics
| Avg. Volume (3 month) | 683.76K USD |
| Avg. Daily Volume (10-Days) | 543.34K USD |
| Shares Outstanding | 105.69M |
| Float | 75.16M |
| Short Ratio | 10.29 |
| % Held by Insiders | 15.31% |
| % Held by Institutions | 58.22% |
| Shares Short | 8.11M |
| Short % of Float | 9.07% |
| Short % of Shares Outstanding | 7.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 41.57% |
| Operating Margin (ttm) | 50.57% |
| Gross Margin | 100.00% |
| EBITDA Margin | 51.29% |
Management Effectiveness
| Return on Assets (ttm) | 18.38% |
| Return on Equity (ttm) | 27.60% |
Income Statement
| Revenue (ttm) | 236.04M USD |
| Revenue Per Share (ttm) | 2.4 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | 121.08M USD |
| Net Income Avi to Common (ttm) | 98.14M USD |
| Diluted EPS (ttm) | 1.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 430.03M USD |
| Total Cash Per Share (mrq) | 4.07 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.582 |
| Book Value Per Share (mrq) | 4.464 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 171.62M USD |
| Levered Free Cash Flow (ttm) | 129.96M USD |
Profile of POINT Biopharma Global
| Country | United States |
| State | IN |
| City | Indianapolis |
| Address | 4850 West 78th Street |
| ZIP | 46268 |
| Phone | 647 812 2417 |
| Website | https://www.pointbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 129 |
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Q&A For POINT Biopharma Global Stock
What is a current PNT stock price?
POINT Biopharma Global PNT stock price today per share is 12.5 USD.
How to purchase POINT Biopharma Global stock?
You can buy PNT shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for POINT Biopharma Global?
The stock symbol or ticker of POINT Biopharma Global is PNT.
Which industry does the POINT Biopharma Global company belong to?
The POINT Biopharma Global industry is Biotechnology.
How many shares does POINT Biopharma Global have in circulation?
The max supply of POINT Biopharma Global shares is 106.57M.
What is POINT Biopharma Global Price to Earnings Ratio (PE Ratio)?
POINT Biopharma Global PE Ratio is 0.00000000 now.
What was POINT Biopharma Global earnings per share over the trailing 12 months (TTM)?
POINT Biopharma Global EPS is 0 USD over the trailing 12 months.
Which sector does the POINT Biopharma Global company belong to?
The POINT Biopharma Global sector is Healthcare.
POINT Biopharma Global PNT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
| NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}